Progress at Okapi’s African ventures

|

Published 22-JUN-2018 14:59 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

This product is classified as ‘very high risk’ in nature due to its location and geopolitical situation of the region. Finfeed advises that extra caution should be taken when deciding whether to engage in this product, however if you are not sure whether it is suitable for you we suggest you seek independent financial advice.

Okapi Resources Limited (ASX:OKR) today updated the market with an operational update on its Mambasa Gold Project, as well as providing an update on its legal due diligence at the Katanga Cobalt/Copper Project.

Western Australian-based Okapi is focused on the discovery and commercialisation of the above mineral deposits in the Democratic Republic of the Congo (DRC), as well as its Crackerjack Project in WA.

With a team of professionals having an exemplary record of success operating in those locations, OKR’s primary objective is to discover and develop mineral resources from its current portfolio. The company has carefully selected its initial projects that come with historical workings and excellent results.

However it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.

Mambasa Gold Project

OKR reports that it has now collected some 499 infill soil samples, including 12 rock chips, and 24 QAQC (quality control/quality control) samples.

These samples are being prepared on site for a duplicate to be left with the local Mines Department, as is required by law, with all 499 samples being readied for transport to Lubumbashi for sample preparation at ALS Laboratories Lubumbashi and forwarding to ASL South Africa for determination of precious (gold, silver) and other pathfinder elements.

The company will provide results as soon as they are received and analysed by senior technical staff.

It is hoped that results of the infill soil sampling will allow targeting of scout drill holes at the project which will be undertaken in the next phase of exploration work at site.

Infill Soil Sampling Completed at the Mambasa Gold Project

Katanga Cobalt Copper Project

OKR has now secured a further extension to finalise legal due diligence, having up to 180 business days from the original agreement date of 18 January 2018. This extension was mutually agreed with the vendor, Rubamin FZC, UAE and its DRC subsidiary, Rubaco Societe a Responsabilitee. It will provide additional time to present the legal documentation required.

OKR confirms that it remains positive about the technical aspects of the two projects and will continue with limited ongoing field work to further assess the assets.

Further, OKR is pursuing a growth strategy that aims to appraise and secure further exploration and development opportunities within gold and mineral endowed districts.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X